I N T R O D U C T I O N
Preemptive kidney transplantation, (transplantation prior to the initiation of dialysis) is regarded as the optimal mode of kidney transplantation, based upon registry analyses that demonstrate superior graft and patient survival compared with those who receive kidney transplants following a period of dialysis [1, 2] . Similarly, for patients with type 1 diabetes (T1DM), superior outcomes have also been demonstrated in those who undergo preemptive simultaneous pancreaskidney (SPK) transplant compared with those receiving an SPK transplant non-preemptively [3, 4] . While the reasons for this survival advantage are the subject of investigation, these outcomes have formed the basis for initiatives supporting early referral for transplantation and education directed at promoting living donation [5] .
Given these data supporting preemptive transplantation, for the patient with T1DM approaching dialysis who has a living donor the decision to proceed with the living donor kidney (LDK) transplant or wait for an SPK becomes problematic. While debate exists regarding the survival advantages of LDK versus SPK [6, 7] transplantation, recent reports suggest that SPK transplantation, particularly in the setting of a functional pancreas transplant, may translate into greater long-term survival compared with LDK [8] [9] [10] [11] transplantation. When specifically focusing upon preemptive transplant outcomes, we have recently reported that SPK and LDK outcomes are comparable [12] . If the decision to wait for an SPK is considered, it is not known how much risk is assumed by the brief period of dialysis prior to SPK transplantation, compared with accepting an LDK either prior to or shortly after starting dialysis.
To determine whether the accumulation of pre-transplant dialysis time (DT) mitigates the potential benefits of waiting for an SPK rather than proceeding with an LDK, we undertook a retrospective analysis of all TIDM recipients of either an LDK transplant or SPK who had received their transplant preemptively or after up to 2 years from the initiation of dialysis. Our hypothesis was that the pre-transplant DT would have a negative impact upon post-transplant survival for both SPK and LDK recipients, but that this impact would be sufficiently minimal in the SPK cohort to support waiting for an SPK versus preemptive LDK transplantation.
M AT E R I A L S A N D M E T H O D S

Patients
Using the Organ Procurement Transplant Network/ United Network for Organ Sharing (OPTN/UNOS) database (as of 31 March 31 2012), all adult (≥18 years old) type I diabetic recipients with at least one follow-up report who underwent either an LDK or an SPK transplant were identified. Patients with a history of any prior organ transplantation were excluded. In order to include only those kidney recipients who were also potential candidates for pancreas transplantation, only those who were placed on the pancreas waiting list before or by the time of their kidney transplant were included in the study. The pre-transplant dialysis status from transplant registration reports was available for 17 288 recipients. After excluding patients with a pre-transplant DT of >2 years, a total of 13 241 LDK and SPK recipients remained. Because previous studies have noted improved patient survival following SPK transplant since 2000 [6, 8, 9] , we chose to restrict the study population to only those who received a transplant between 1 January 2000 and the end of the study period on 31 March 2011. The final study population consisted of 1381 LDK and 5441 SPK recipients.
S TAT I S T I CA L M E T H O D S
Baseline recipient, donor and transplant characteristics were described using medians (with 25th and 75th percentiles) or frequencies where appropriate. The Kruskal-Wallis and chisquare tests were used to compare for significant differences in continuous and categorical variables, respectively. Graft and patient survival were described using the Kaplan-Meier product limit method and the differences were evaluated using the log-rank test. The primary endpoints were 7-year post-transplant patient and kidney allograft survival. For patient survival, patients were followed up until death or last follow-up. Kidney graft survival was determined from the date of transplantation to the date of death, kidney failure (defined as re-transplantation or return to dialysis) or last follow-up. For death-censored kidney survival, patients were censored if they died with a functional graft.
Hazard ratios and 95% confidence intervals for patient death and death-censored kidney graft failure were calculated using Cox proportional hazards models. 
R E S U LT S
The study population was comprised of adult T1DM primary transplant candidates listed for pancreas transplantation who received either an LDK (n = 1381) or an SPK (n = 5441) between 2000 and 2011, prior to the accumulation of >2 years of DT. This time constraint was considered as the maximum time that a patient would consider waiting for an SPK prior to receiving an LDK if available, in order to compare outcomes of preemptive LDK with SPK transplantation following increasing times of DT accrual. Demographic information from the study population is listed in Table 1 . Preemptive LDK recipients were slightly older and had a slightly higher BMI than the other cohorts, features that likely contributed to the selection of an LDK rather than an SPK transplant due to the association of these factors with poorer SPK transplant outcomes [6, 13, 14] . A higher percentage of black recipients accrued DT of 1-2 years in both LDK and SPK cohorts, potentially as a result of known disadvantages related to blood type and human leukocyte antigen (HLA) matching [15, 16] . Aside from the differences in donor source, those undergoing an SPK transplant had a higher degree of HLA mismatch and were more likely to receive depleting antibody induction and maintenance immunosuppression that included CNIs and corticosteroids. SPK recipients with <1 year of dialysis had a shorter waiting time than the other SPK cohorts, potentially a reflection of earlier referral and longer waiting time for the preemptive cohort, and more difficulty in blood type or HLA matching in the cohort accruing 1-2 years of dialysis. 
O R I G I N A L A R T I C L E
D i a l y s i s t i m e a n d t r a n s p l a n t o u t c o m e s i n T 1 D M Figure 1 shows 7-year patient survival for (i) LDK recipients alone, (ii) SPK recipients alone and (iii) preemptive LDK recipients compared with all subgroups of SPK recipients, stratified by DT. Figure 1a demonstrates patient survival to be inferior in the LDK recipients with 1-2 years of DT compared with preemptive LDK transplantation (7-year unadjusted survival 76% versus 87%, respectively, P = 0.009). Figure 1b demonstrates an earlier impact upon unadjusted patient survival with DT in SPK cohorts, as both SPK recipients with 0-1 years of prior DT and SPK recipients with 1-2 years of DT had inferior survival (7-year unadjusted survival 84%) compared with preemptive SPK recipients (7-year unadjusted survival 89%, P = 0.01 versus SPK 0-1 year DT, P < 0.001 versus SPK 1-2 year DT). Finally, Figure 1c demonstrates comparable survival in preemptive cohorts (P = 0.46), and no difference in survival comparing SPK recipients with 0-1 year DT or 1-2 year DT to preemptive LDK recipients (84% versus 84% versus 87%, respectively, P = 0.31 versus SPK DT 0-1 year, P = 0.14 versus SPK 1-2 years).
Given prior registry data that have indicated an association of pre-transplant DT with kidney graft survival, a similar analysis was performed for kidney graft survival ( Figure 2 ) and death-censored kidney graft survival (Figure 3) . Figure 2 shows 7-year kidney graft survival for (i) LDK recipients alone, (ii) SPK recipients alone and (iii) preemptive LDK recipients compared with all subgroups of SPK recipients, stratified by DT. Figure 2a again demonstrates graft survival that is inferior in the LDK recipients with 1-2 years of DT compared with preemptive LDK recipients (7-year unadjusted graft survival 60% versus 76%, respectively, P = 0.004). The LDK cohort with 0-1 year DT had an intermediate and nonsignificant difference in kidney graft survival versus preemptive LDK transplantation (70% vs 76%, P = 0.62). Figure 2b shows statistically significant but clinically smaller differences in kidney graft survival within groups with accrued DT (7-year unadjusted graft survival 77% versus 70% versus 73% for preemptive SPK, SPK with 0-1 year DT and SPK with 1-2 year DT, P = 0.05 and 0.02 versus preemptive SPK, respectively). Finally, Figure 2c demonstrates no statistically significant differences in 7-year kidney graft survival when comparing preemptive LDK (76%) with preemptive SPK (77%, P = 0.86) transplants, SPK transplants with 0-1 year DT (70%, P = 0.23) or SPK with 1-2 year DT (73%, P = 0.17). When examining death-censored kidney graft survival among these cohorts, Figure 3 clarifies that the differences seen in Figure 2 were primarily driven by patient death rather than kidney graft loss, as none of the comparisons when censoring for death provided statistically different outcomes. Although not statistically different, there was a 9% difference in graft survival between preemptive LDK transplantation and LDK transplantation with 1-2 years DT (Figure 3a) . In total, the unadjusted survival analyses of Figures 1-3 suggest that DT is associated with lower patient survival following both SPK and LDK transplantation, perhaps to a greater degree in the LDK cohort.
To more clearly define the risk of DT accrual upon patient and kidney graft survival, and to account for the numerous differences in baseline characteristics among LDK and SPK cohorts, an assessment of the risk of patient death and kidney graft loss by DT was performed using multivariate analysis. Table 2 represents hazard ratios for survival and kidney graft loss using preemptive LDK as the reference cohort, compared with SPK with various DT accrual ( preemptive, DT 0-1 year, and DT 1-2 years). Separate analyses were performed accounting for recipient differences (case-mix adjusted), additional donor variables and additional immunosuppression medication use. No significant differences in patient survival were identified using any of these adjusted models. Death-censored kidney graft survival was statistically significantly different only when the drug-adjusted multivariate analysis was performed, favoring preemptive LDK over SPK with dialysis accrual (hazard ratio 1.52 for SPK with 0-1 year DT, P = 0.02, and hazard ratio 1.42 for SPK with 1-2 year DT, P = 0.05), suggesting that the differences in baseline immunosuppression (in particular, differences in induction 
D i a l y s i s t i m e a n d t r a n s p l a n t o u t c o m e s i n T 1 D M F I G U R E 1 : Seven-year patient survival for (a) LDK recipients alone, (b) SPK recipients alone and (c) preemptive LDK recipients compared with all subgroups of SPK recipients, stratified by DT ( preemptive, 0-1 year dialysis, 1-2 year dialysis). therapy and corticosteroid use noted in Table 1 ) were primary determinants of these differences in kidney graft survival.
D I S C U S S I O N
The purpose of this analysis was to determine the impact of accrual of up to 2 years of DT upon post-transplant SPK and LDK outcomes in T1DM recipients, and to consider whether there are differences in survival that would support SPK transplantation with up to 2 years of DT over preemptive LDK transplantation. This question reflects the clinical scenario in which a potential SPK candidate may consider waiting for an SPK and undergo dialysis rather than accepting an LDK in order to gain the potential advantages that euglycemia may offer. We find that there is little to no patient survival advantage (or disadvantage) achieved with SPK transplantation in this scenario with up to 7 years of follow-up. The lack of a clear survival advantage with one transplant modality versus another should encourage patients and transplant centers to focus upon specific individual circumstances of the potential LDK/SPK recipient (e.g. qualityof-life issues related to diabetes control, potential for intolerance of dialysis, comorbidities that may predispose to complications of larger surgery) when discussing transplant options. If individual factors support pursuit of a pancreas transplant, these data suggest that it is not unreasonable to wait for up to 
O R I G I N A L A R T I C L E
D i a l y s i s t i m e a n d t r a n s p l a n t o u t c o m e s i n T 1 D M 2 years of dialysis for an SPK transplant in terms of posttransplant outcomes. There were no statistically significant survival differences between preemptive LDK and SPK when performed with accrued waiting time of up to 2 years. Our multivariate analyses suggested a positive association of preemptive LDK transplantation and kidney graft survival only after including induction and maintenance immunosuppression as variables in the analysis ( Table 2 ), suggesting that baseline differences in immunosuppression may contribute to improved LDK transplant outcomes. Of these, the use of depleting antibody induction formed the greatest difference in immunosuppression management between transplant modalities at baseline. We have previously reported the lack of effect of antibody induction upon living donor graft survival [17] with potentially worse graft survival using alemtuzumab versus IL2 receptor antagonists [18] . These findings are different from the experience with SPK transplantation, in which induction agents have been associated with improved kidney and pancreas graft survival [19, 20] . Given the differential effects of induction therapy on LDK versus SPK transplant recipients, this should also be a consideration for patients and providers when discussing treatment options. Other features that may influence patient and physician decision-making include recipient age and BMI, and selection of optimal donor characteristics [20] [21] [22] .
We and others have demonstrated the potential value of pancreas transplant function on long-term survival for SPK transplant candidates [23, 24] , and have demonstrated similar outcomes of LDK and SPK transplantation when performed preemptively [9, 12] . This study adds to this growing body of data and suggests that for the patient who is not yet on dialysis, SPK transplantation is at least equivalent if not superior to LDK transplantation, but once DT is introduced there is no clear advantage of one strategy compared with the other from a survival standpoint. However, it must be acknowledged that this analysis does not take into account other potential benefits of SPK transplant related to euglycemia such as quality of life [25, 26] or the potential to slow progression of secondary complications of diabetes or cardiovascular disease [27, 28] .
There are limitations to our study that should be recognized. Given the retrospective nature of this study, one cannot be assured that patients who undergo SPK transplantation are similar to those who have a living donor option and proceed with a living donor transplant. In addition to the differences noted in Table 1 , glycemic control and social support systems may be quite different between the two groups that, without prospective collection and randomization, will continue to limit the general applicability of retrospective analyses. Our findings may underestimate the advantages of preemptive LDK over the accrual of DT with subsequent SPK, since our study only addressed the association of pre-transplant dialysis upon post-transplant survival and did not include the pre-transplant risks (i.e. the potential of health deterioration or death while remaining on dialysis that would preclude transplantation). Another unaccounted-for characteristic within the LDK cohort is the potential for a pancreas after living donor kidney transplant (PALK), a subset that was not specifically segregated within this analysis but has been analyzed by our group and others [29, 30] . In general, PALK recipients have been shown to have superior outcomes in recent analyses than LDK cohorts, so it is likely that the segregation of our current LDK cohort would produce outcomes that supported SPK rather than LDK transplantation alone in the absence of PALK. Additionally, differences in living versus deceased kidney donor 'quality' and its impact upon outcomes are difficult to compare, e.g. LDKs have trivial cold ischemia time and low delayed function rates, and brain death may have pro-inflammatory effects upon the graft that are not quantified. However, for the purpose of this comparison the SPK cohort also had low delayed graft function rates and had comparable creatinine at 1 year, supporting the concept that kidneys from SPK donors may confer graft outcomes similar to living donor outcomes [31] . Finally, it is possible that our 7-year analysis is not a sufficient time post-transplant to demonstrate the impact that euglycemia may have upon graft or patient survival despite the accrual of DT [6, 10] .
The decision for a patient with T1DM and chronic kidney disease (CKD) not yet on dialysis to wait for an SPK or to proceed with LDK is dependent upon a number of subjective factors, including (i) assessment of the impact of potential euglycemia on the individual (both physiologically and psychologically), (ii) the individual patient's willingness to undergo a larger, more risky surgical procedure and (c) the waiting time necessary to receive an SPK transplant. Our study primarily addresses this final consideration. If one commits to waiting for an SPK and subsequent waiting time leads to the consideration of initiating dialysis, patients may be reasonably advised that survival data suggest similar post-transplant survival with SPK up to 2 years following initiation of dialysis compared with preemptive LDK. While there are regional variations in the waiting time for an SPK transplant in the USA, waiting times <1 year are not unusual, particularly for certain blood types. Patients with T1DM and CKD should be referred early to transplant centers, preferably with glomerular filtration rates near 20 mL/min in order to fully explore their transplant options.
CO N C L U S I O N S
While SPK and LDK outcomes are quite similar when performed preemptively, DT negatively impacts outcomes with each of these modalities. The absence of clear advantage or disadvantage with SPK following accumulation of DT compared with preemptive LDK leads to the conclusion that individual patient circumstances and preferences should dictate transplant modality, rather than a clear survival benefit of one strategy versus the other.
